Developer docs
API playgroundTry for free, no card

Search company profiles

Galt Pharmaceuticals

Full company profile

uuid000oqaw

Namestring
Galt Pharmaceuticals
Legal namestring
Galt Pharmaceuticals
Websiteurl
galtrx.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Galt Pharmaceuticals is a privately held, self-funded specialty pharmaceutical company founded in 2016 in Atlanta, Georgia by pharmacists Dr. Barry Patel and Dr. Wade Smith. The company develops and commercializes prescription medications that target unmet clinical needs, focusing on non-opioid musculoskeletal pain (Norgesic, Orphengesic Forte), inflammatory arthritis (Tolectin), insomnia (Doral), and oral thrush (Oravig). Its core competency is reformulating and re-commercializing proven therapies that larger companies have discontinued or de-prioritized, supported by in-house regulatory expertise across NDA, ANDA, and sANDA pathways.

The company's commercial architecture is anchored by the "Phranchise" distribution model — described as the pharmaceutical industry's first franchising concept — in which 55 U.S. territories are operated by entrepreneur-owners (Phranchisees) who employ local sales and marketing staff to engage healthcare providers, while Galt retains centralized drug research, regulatory, compliance, and supply-chain functions. A parallel network of independent partner pharmacies handles dispensing, supported by the Galt Direct Help Desk and a CloudTop Health prior-authorization workflow that produces a one-page request to prescribers. Patient access is facilitated via cash-pay pricing starting at $30, $0 copay support, and deductible-credit programs targeting uninsured and underinsured patients.

Galt generates revenue from prescription product sales across its four marketed brands plus licensing/franchise fees from Phranchisees, and pursues additional growth through an in-house business-development function that actively seeks licensing, partnership, and acquisition of marketed and development-stage medicines. Operating as part of the Galt Companies parent alongside Galt Phranchise Systems, the company is led by founders Patel (CEO) and Smith (Chairman) alongside a COO with an enterprise-systems background and a Chief Regulatory Officer, with a 4-day, 36-hour workweek as a stated cultural differentiator.

Short descriptiontext

Galt Pharmaceuticals is a private, self-funded specialty pharma founded in 2016 in Atlanta that develops and commercializes prescription medications — including Norgesic, Tolectin, Oravig, and Doral — targeting non-opioid pain, arthritis, insomnia, and oral thrush, distributed via an industry-first franchised-Phranchise model across 55 U.S. territories.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAtlanta, United States
HQ citystring
Atlanta
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
prescription pharmaceuticals, non-opioid pain management, pharmaceutical franchise model, specialty drug commercialization, drug reformulation services
Industry3 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical product sales
TypeOne Time License
Description

Galt generates revenue primarily from the sale of prescription medications including Norgesic (orphenadrine citrate/aspirin/caffeine), Tolectin (tolmetin sodium), Doral (quazepam), and Oravig (miconazole buccal). Products are sold through a network of partner pharmacies and the Phranchise distribution system.

galtrx.com
2Phranchise licensing fees
TypeLicensing Royalties
Description

Galt Phranchise Systems licenses the Phranchise model to entrepreneurs who build local pharmaceutical businesses. Franchisees gain access to Galt's product portfolio, CRM platforms, marketing support, and operational systems in exchange for licensing fees.

galtrx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure
Pricing details1 tier
1Patient Assistance Program / Cash Pay — $30 per prescription
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Patients who are uninsured or underinsured and not able to receive Galt Products through insurance can fill prescriptions via Galt's Patient Assistance Program for as little as $30 with no exclusion criteria.

galtrx.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1Norgesic
Description

Orphenadrine Citrate 25mg, Aspirin 385mg, Caffeine 30mg Tablets for non-opioid acute musculoskeletal pain relief

galtrx.com
+5 more records
Core offering1 text field

Galt Pharmaceuticals develops and commercializes prescription medications addressing unmet clinical needs across non-opioid pain management (Norgesic, Tolectin), insomnia (Doral), and oral thrush (Oravig). The company reformulates and re-commercializes proven therapies previously discontinued by larger pharmaceutical firms, and distributes them through a proprietary pharmaceutical franchise (Phranchise) model that places entrepreneur-owned territories in local communities alongside a network of trained independent partner pharmacies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 2024 was Galt's best year after eight years of operation, with record sales for Doral and Orphengesic Forte
+2 more records
Product overview1 text field

Galt Pharmaceuticals is a specialty pharmaceutical company that develops and commercializes prescription medications addressing unmet clinical needs. The company's portfolio consists of four currently marketed products: Norgesic (non-opioid acute musculoskeletal pain), Tolectin (osteoarthritis and rheumatoid arthritis), Oravig (oral thrush), and Doral (insomnia). Additionally, the company has two pipeline candidates in development: GA-2601 for migraine and GA-2701 for tension headaches. Galt operates a unique pharmaceutical franchising model ('Phranchise') to distribute products through local entrepreneurs and independent pharmacies, differentiating from traditional big pharma distribution.

Product and service5 records
1Norgesic
CategoryMarketed Product (Prescription Pharmaceutical)
Description

Orphenadrine Citrate 25 mg, Aspirin 385 mg, Caffeine 30 mg Tablets for non-opioid, non-controlled, multimodal relief of mild to moderate acute musculoskeletal pain. Marketed to physicians and prescribers as an alternative to opioid pain therapies.

2Tolectin
CategoryMarketed Product (Prescription Pharmaceutical)
Description

Tolmetin Sodium 400 mg Capsules and 600 mg Tablets; NSAID-based anti-inflammatory treatment for osteoarthritis and rheumatoid arthritis. Marketed as a non-opioid alternative for arthritis-related inflammatory pain.

3Oravig
CategoryMarketed Product (Prescription Pharmaceutical, Acquired Brand)
Description

Miconazole Buccal 50 mg Tablets for the treatment of oral thrush (oropharyngeal candidiasis). The first and only muco-adhesive buccal tablet formulation of miconazole approved in the United States; marketed primarily to oncology and primary care prescribers.

4Doral
CategoryMarketed Product (Prescription Pharmaceutical)
Description

Quazepam 15 mg Tablets; FDA-approved sedative-hypnotic medication used for the treatment of insomnia. Marketed to prescribers and supported through Galt's PAP and partner pharmacy network.

5Galt Phranchise Systems (Pharmaceutical Franchise Licensing)
CategoryFranchise Licensing / Distribution Model
Description

The industry's first pharmaceutical franchise concept that licenses the Galt Phranchise model to healthcare entrepreneurs. Franchisees gain access to Galt's product portfolio, CRM platforms, marketing support, and operational systems in exchange for licensing fees, and operate in designated territories employing their own sales and marketing associates.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeOthersAnnounced on2020-12-02
Description

Galt Pharmaceuticals acquired Oravig (Miconazole Buccal Tablets 50mg), the first and only orally-dissolving buccal tablet for oral thrush, from Fortovia Therapeutics, effective December 2, 2020. Oravig became the third product in Galt's portfolio and fits the Phranchise distribution model.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Galt Pharmaceuticals contracts with CloudTop Health to streamline the Prior Authorization process. Once a case is initiated by a Galt Partner Pharmacy, the provider office receives a custom-tailored 1-page request for patient diagnosis and medical history. CloudTop handles filing the case to insurance and communication to the pharmacy, eliminating this burden from provider office staff.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Galt Pharmaceuticals partners with a network of independent pharmacies that are specially trained in patient communication and insurance processing to help each patient attain the lowest possible price for their prescription. These pharmacies avoid callbacks to offices regarding product availability or price that are common with large chain pharmacies. Galt prioritizes independent pharmacies for their patient responsiveness compared to chain pharmacies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Galt Phranchise Systems is the franchise arm of Galt Companies, the parent organization of Galt Pharmaceuticals. It enables healthcare entrepreneurs to build localized, community-driven pharmaceutical businesses under the Galt brand. Phranchisees operate in designated territories and employ their own sales and marketing associates, providing education to local healthcare providers while Galt manages drug research, regulatory approval, compliance, and supply chain.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

A specialty pharmaceutical company focused on commercializing niche prescription products, often reformulating or acquiring deprioritized assets. Similar size and product-portfolio strategy to Galt, with comparable focus on underserved therapeutic areas and a lean commercial footprint.

TypeDirect peer
Description

Specialty and generic pharmaceutical company that acquires, develops, and commercializes prescription medicines, including legacy and reformulated products. Closely comparable to Galt's strategy of reviving shelved therapies and building a specialty pharma portfolio.

TypeDirect peer
Description

Specialty pharmaceutical company that acquires and commercializes FDA-approved prescription products for niche therapeutic areas. Similar focus on small sales forces commercializing differentiated products in pain, GI, and other specialties — directly comparable to Galt's positioning.

TypeDirect peer
Description

Specialty pharmaceutical company focused on acquiring and re-commercializing prescription products, including legacy brands that have been deprioritized by larger manufacturers. Direct strategic parallel to Galt's reformulation-and-relaunch model.

TypeDirect peer
Description

Specialty pharmaceutical company that acquires and markets niche prescription products, with a track record of reviving under-promoted brands. Comparable to Galt in size, therapeutic focus, and strategy of reclaiming value from shelved therapies.

TypeDirect peer
Description

Specialty pharmaceutical company developing and commercializing differentiated injectable and hospital products, often improving formulations of existing molecules. Mirrors Galt's reformulation strategy and specialty commercial model.

TypeDirect peer
Description

Specialty pharmaceutical company focused on acquiring, developing, and commercializing branded prescription products for dermatology and other niche therapeutic areas. Similar profile to Galt — small specialty pharma with a focused portfolio and growth-by-acquisition strategy.

8Endo International
TypeBroad incumbent
Description

Large specialty and generic pharmaceutical company with a diversified portfolio in pain, urology, and other specialties. Endo operates at much greater scale but competes in overlapping therapeutic areas like musculoskeletal pain, making it a relevant broad incumbent for Galt.

TypeBroad incumbent
Description

Major generic and specialty pharmaceutical manufacturer with a broad portfolio including pain, CNS, and antifungal products. Overlaps with Galt's therapeutic areas and serves as a benchmark for how a larger specialty/generic competitor can scale reformulated products.

TypeBroad incumbent
Description

Large diversified pharmaceutical company with specialty pharma, generics, and consumer health segments. Owns the former Vertical Pharmaceuticals franchise business, providing a relevant scale benchmark for what Galt's Phranchise model could grow into over the long term.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Galt Pharmaceuticals

Specialty Pharmaceuticalsgaltrx.com

Galt Pharmaceuticals is a private, self-funded specialty pharma founded in 2016 in Atlanta that develops and commercializes prescription medications — including Norgesic, Tolectin, Oravig, and Doral — targeting non-opioid pain, arthritis, insomnia, and oral thrush, distributed via an industry-first franchised-Phranchise model across 55 U.S. territories.

What Galt Pharmaceuticals does

Galt Pharmaceuticals is a privately held, self-funded specialty pharmaceutical company founded in 2016 in Atlanta, Georgia by pharmacists Dr. Barry Patel and Dr. Wade Smith. The company develops and commercializes prescription medications that target unmet clinical needs, focusing on non-opioid musculoskeletal pain (Norgesic, Orphengesic Forte), inflammatory arthritis (Tolectin), insomnia (Doral), and oral thrush (Oravig). Its core competency is reformulating and re-commercializing proven therapies that larger companies have discontinued or de-prioritized, supported by in-house regulatory expertise across NDA, ANDA, and sANDA pathways.

The company's commercial architecture is anchored by the "Phranchise" distribution model — described as the pharmaceutical industry's first franchising concept — in which 55 U.S. territories are operated by entrepreneur-owners (Phranchisees) who employ local sales and marketing staff to engage healthcare providers, while Galt retains centralized drug research, regulatory, compliance, and supply-chain functions. A parallel network of independent partner pharmacies handles dispensing, supported by the Galt Direct Help Desk and a CloudTop Health prior-authorization workflow that produces a one-page request to prescribers. Patient access is facilitated via cash-pay pricing starting at $30, $0 copay support, and deductible-credit programs targeting uninsured and underinsured patients.

Galt generates revenue from prescription product sales across its four marketed brands plus licensing/franchise fees from Phranchisees, and pursues additional growth through an in-house business-development function that actively seeks licensing, partnership, and acquisition of marketed and development-stage medicines. Operating as part of the Galt Companies parent alongside Galt Phranchise Systems, the company is led by founders Patel (CEO) and Smith (Chairman) alongside a COO with an enterprise-systems background and a Chief Regulatory Officer, with a 4-day, 36-hour workweek as a stated cultural differentiator.

Galt Pharmaceuticals firmographics

Firmographics
Name
Galt Pharmaceuticals
Legal name
Galt Pharmaceuticals
Website
https://galtrx.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Galt Pharmaceuticals is a private, self-funded specialty pharma founded in 2016 in Atlanta that develops and commercializes prescription medications — including Norgesic, Tolectin, Oravig, and Doral — targeting non-opioid pain, arthritis, insomnia, and oral thrush, distributed via an industry-first franchised-Phranchise model across 55 U.S. territories.
Ownership category
akta.pro rank

Galt Pharmaceuticals industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

Keywords

  • Prescription pharmaceuticals
  • Non-opioid pain management
  • Pharmaceutical franchise model
  • Specialty drug commercialization
  • Drug reformulation services

Where Galt Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Atlanta
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Galt Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure

Revenue model

  1. Pharmaceutical product sales: Galt generates revenue primarily from the sale of prescription medications including Norgesic (orphenadrine citrate/aspirin/caffeine), Tolectin (tolmetin sodium), Doral (quazepam), and Oravig (miconazole buccal). Products are sold through a network of partner pharmacies and the Phranchise distribution system.
  2. Phranchise licensing fees: Galt Phranchise Systems licenses the Phranchise model to entrepreneurs who build local pharmaceutical businesses. Franchisees gain access to Galt's product portfolio, CRM platforms, marketing support, and operational systems in exchange for licensing fees.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goPatient Assistance Program / Cash Pay — $30 per prescription

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Galt Pharmaceuticals product offering

Product offering

Core offering

Galt Pharmaceuticals develops and commercializes prescription medications addressing unmet clinical needs across non-opioid pain management (Norgesic, Tolectin), insomnia (Doral), and oral thrush (Oravig). The company reformulates and re-commercializes proven therapies previously discontinued by larger pharmaceutical firms, and distributes them through a proprietary pharmaceutical franchise (Phranchise) model that places entrepreneur-owned territories in local communities alongside a network of trained independent partner pharmacies.

Product overview

Galt Pharmaceuticals is a specialty pharmaceutical company that develops and commercializes prescription medications addressing unmet clinical needs. The company's portfolio consists of four currently marketed products: Norgesic (non-opioid acute musculoskeletal pain), Tolectin (osteoarthritis and rheumatoid arthritis), Oravig (oral thrush), and Doral (insomnia). Additionally, the company has two pipeline candidates in development: GA-2601 for migraine and GA-2701 for tension headaches. Galt operates a unique pharmaceutical franchising model ('Phranchise') to distribute products through local entrepreneurs and independent pharmacies, differentiating from traditional big pharma distribution.

Differentiator

Problem solved

Functional benefit

Brands

  • Norgesic: Orphenadrine Citrate 25mg, Aspirin 385mg, Caffeine 30mg Tablets for non-opioid acute musculoskeletal pain relief
  • Tolectin
  • Oravig
  • Doral
  • Galt Phranchise Systems
  • Galt Direct Help Desk

Products and services

  • Norgesic Orphenadrine Citrate 25 mg, Aspirin 385 mg, Caffeine 30 mg Tablets for non-opioid, non-controlled, multimodal relief of mild to moderate acute musculoskeletal pain. Marketed to physicians and prescribers as an alternative to opioid pain therapies.
  • Tolectin Tolmetin Sodium 400 mg Capsules and 600 mg Tablets; NSAID-based anti-inflammatory treatment for osteoarthritis and rheumatoid arthritis. Marketed as a non-opioid alternative for arthritis-related inflammatory pain.
  • Oravig Miconazole Buccal 50 mg Tablets for the treatment of oral thrush (oropharyngeal candidiasis). The first and only muco-adhesive buccal tablet formulation of miconazole approved in the United States; marketed primarily to oncology and primary care prescribers.
  • Doral Quazepam 15 mg Tablets; FDA-approved sedative-hypnotic medication used for the treatment of insomnia. Marketed to prescribers and supported through Galt's PAP and partner pharmacy network.
  • Galt Phranchise Systems (Pharmaceutical Franchise Licensing) The industry's first pharmaceutical franchise concept that licenses the Galt Phranchise model to healthcare entrepreneurs. Franchisees gain access to Galt's product portfolio, CRM platforms, marketing support, and operational systems in exchange for licensing fees, and operate in designated territories employing their own sales and marketing associates.

Quantifiable outcome

  • 2024 was Galt's best year after eight years of operation, with record sales for Doral and Orphengesic Forte
  • +2 more outcomes

Companies that use Galt Pharmaceuticals

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Galt Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Galt Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Fortovia TherapeuticscoreOthers · 2 December 2020Galt Pharmaceuticals acquired Oravig (Miconazole Buccal Tablets 50mg), the first and only orally-dissolving buccal tablet for oral thrush, from Fortovia Therapeutics, effective December 2, 2020. Oravig became the third product in Galt's portfolio and fits the Phranchise distribution model.
  • CloudTop HealthcoreImplementation/ SI/ Consulting PartnerGalt Pharmaceuticals contracts with CloudTop Health to streamline the Prior Authorization process. Once a case is initiated by a Galt Partner Pharmacy, the provider office receives a custom-tailored 1-page request for patient diagnosis and medical history. CloudTop handles filing the case to insurance and communication to the pharmacy, eliminating this burden from provider office staff.
  • Independent Pharmacy PartnerscoreChannel Partner/ Reseller/ DistributorGalt Pharmaceuticals partners with a network of independent pharmacies that are specially trained in patient communication and insurance processing to help each patient attain the lowest possible price for their prescription. These pharmacies avoid callbacks to offices regarding product availability or price that are common with large chain pharmacies. Galt prioritizes independent pharmacies for their patient responsiveness compared to chain pharmacies.
  • Galt Phranchise SystemscoreStrategic or Co-development PartnerGalt Phranchise Systems is the franchise arm of Galt Companies, the parent organization of Galt Pharmaceuticals. It enables healthcare entrepreneurs to build localized, community-driven pharmaceutical businesses under the Galt brand. Phranchisees operate in designated territories and employ their own sales and marketing associates, providing education to local healthcare providers while Galt manages drug research, regulatory approval, compliance, and supply chain.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Galt Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Aytu BioPharma: A specialty pharmaceutical company focused on commercializing niche prescription products, often reformulating or acquiring deprioritized assets. Similar size and product-portfolio strategy to Galt, with comparable focus on underserved therapeutic areas and a lean commercial footprint.
  • ANI Pharmaceuticals: Specialty and generic pharmaceutical company that acquires, develops, and commercializes prescription medicines, including legacy and reformulated products. Closely comparable to Galt's strategy of reviving shelved therapies and building a specialty pharma portfolio.
  • Cumberland Pharmaceuticals: Specialty pharmaceutical company that acquires and commercializes FDA-approved prescription products for niche therapeutic areas. Similar focus on small sales forces commercializing differentiated products in pain, GI, and other specialties — directly comparable to Galt's positioning.
  • Almatica Pharma: Specialty pharmaceutical company focused on acquiring and re-commercializing prescription products, including legacy brands that have been deprioritized by larger manufacturers. Direct strategic parallel to Galt's reformulation-and-relaunch model.
  • Vertical Pharmaceuticals: Specialty pharmaceutical company that acquires and markets niche prescription products, with a track record of reviving under-promoted brands. Comparable to Galt in size, therapeutic focus, and strategy of reclaiming value from shelved therapies.
  • Eagle Pharmaceuticals: Specialty pharmaceutical company developing and commercializing differentiated injectable and hospital products, often improving formulations of existing molecules. Mirrors Galt's reformulation strategy and specialty commercial model.
  • Journey Medical Corporation: Specialty pharmaceutical company focused on acquiring, developing, and commercializing branded prescription products for dermatology and other niche therapeutic areas. Similar profile to Galt — small specialty pharma with a focused portfolio and growth-by-acquisition strategy.

Broad incumbents

  • Endo International: Large specialty and generic pharmaceutical company with a diversified portfolio in pain, urology, and other specialties. Endo operates at much greater scale but competes in overlapping therapeutic areas like musculoskeletal pain, making it a relevant broad incumbent for Galt.
  • Amneal Pharmaceuticals: Major generic and specialty pharmaceutical manufacturer with a broad portfolio including pain, CNS, and antifungal products. Overlaps with Galt's therapeutic areas and serves as a benchmark for how a larger specialty/generic competitor can scale reformulated products.
  • Bausch Health Companies: Large diversified pharmaceutical company with specialty pharma, generics, and consumer health segments. Owns the former Vertical Pharmaceuticals franchise business, providing a relevant scale benchmark for what Galt's Phranchise model could grow into over the long term.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Galt Pharmaceuticals social profiles

Digital presence

Galt Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Galt Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles5 records

Galt Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Galt Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Galt Pharmaceuticals

What does Galt Pharmaceuticals do?

Galt Pharmaceuticals develops and commercializes prescription medications addressing unmet clinical needs across non-opioid pain management (Norgesic, Tolectin), insomnia (Doral), and oral thrush (Oravig). The company reformulates and re-commercializes proven therapies previously discontinued by larger pharmaceutical firms, and distributes them through a proprietary pharmaceutical franchise (Phranchise) model that places entrepreneur-owned territories in local communities alongside a network of trained independent partner pharmacies.

Is Galt Pharmaceuticals a public or private company?

Galt Pharmaceuticals is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Galt Pharmaceuticals founded?

Galt Pharmaceuticals was founded in 2016. It employs 11 to 50 people.

Where is Galt Pharmaceuticals based?

Galt Pharmaceuticals is headquartered in Atlanta, United States, in the North America region.

How does Galt Pharmaceuticals make money?

Two revenue lines are on record. Pharmaceutical product sales are the primary driver. The others are phranchise licensing fees.

Who are Galt Pharmaceuticals's main competitors?

Direct peers on record are Aytu BioPharma, ANI Pharmaceuticals, Cumberland Pharmaceuticals, Almatica Pharma, Vertical Pharmaceuticals, Eagle Pharmaceuticals and Journey Medical Corporation. Broad incumbents are Endo International, Amneal Pharmaceuticals and Bausch Health Companies.

Does Galt Pharmaceuticals have an API?

No public API is recorded for Galt Pharmaceuticals.

What industry is Galt Pharmaceuticals in?

Galt Pharmaceuticals's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals